Oren Gilad
Chief Executive Officer chez APREA THERAPEUTICS, INC.
Fortune : 2 M $ au 31/03/2024
Profil
Oren Gilad is the founder of Atrin Pharmaceuticals LLC, which was founded in 2011.
He held the title of President, Chief Executive Officer & Director from 2011 to 2022.
Mr. Gilad is also the current President, Chief Executive Officer & Director of Aprea Therapeutics, Inc. since 2022.
Prior to his current role, he was the Chief Executive Officer & President of Atrin Pharmaceuticals, Inc. from 2011 to 2022.
Mr. Gilad has a doctorate degree from the University of Pennsylvania, a doctorate degree from the University of California, Davis, and an undergraduate degree from The Hebrew University of Jerusalem.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
APREA THERAPEUTICS, INC.
6,14% | 28/03/2024 | 333 295 ( 6,14% ) | 2 M $ | 31/03/2024 |
Postes actifs de Oren Gilad
| Sociétés | Poste | Début |
|---|---|---|
| APREA THERAPEUTICS, INC. | Chief Executive Officer | 29/06/2022 |
Anciens postes connus de Oren Gilad
| Sociétés | Poste | Fin |
|---|---|---|
Atrin Pharmaceuticals LLC
 Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | Founder | 01/01/2022 |
Atrin Pharmaceuticals, Inc.
 Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the private company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile. | Chief Executive Officer | 01/01/2022 |
Formation de Oren Gilad
| University of Pennsylvania | Doctorate Degree |
| University of California, Davis | Doctorate Degree |
| The Hebrew University of Jerusalem | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| APREA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Atrin Pharmaceuticals LLC
Atrin Pharmaceuticals LLC BiotechnologyHealth Technology Atrin Pharmaceuticals LLC engages in discovery and development of proprietary medications. It offers ATRN-502, a p53 activator; and ATRN-507, a dual ligand showing specificity and selectivity against cancer cells. The firm also provides Atrize, a platform that offers phenotypic FACS-based screening that is applicable across R&D, clinical applications, and a tool for personalized medicine. The company was founded by Oren Gilad and Kevin D. Smith in 2011 and is headquartered in Doylestown, PA. | Health Technology |
Atrin Pharmaceuticals, Inc.
Atrin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 2012, Atrin Pharmaceuticals, Inc. is a DNA Damage Response development company that focuses on a pipeline of products resulting from a series of novel conformationally restricted macrocyclic molecules. Part of Aprea Therapeutics, Inc., the private company is based in Doylestown, PA. Atrin Pharmaceuticals was acquired by Aprea Therapeutics, Inc. on May 16, 2022 for $1.33 million. The company's products have the highest known potency for inhibiting ATR and exhibit ATR selectivity with potential broad therapeutic profile. | Health Technology |
